SCHEMBL15020607

SCHEMBL15020607

Cc1nn2c(-c3cccc(F)c3)cc(N3CCCC3CO)nc2c1-c1ccc2c(c1)OCO2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGB2 P05107 1/20 0.39
▸ ICAM1 P05362 1/20 0.39
▸ ITGAL P20701 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ CDK1 P06493 1/20 0.37
▸ SCD5 Q86SK9 4/20 0.36
▸ PDCD1 Q15116 1/20 0.36
▸ CD274 Q9NZQ7 1/20 0.36
▸ FPR2 P25090 1/20 0.36
▸ SCN9A Q15858 1/20 0.36
▸ MAPT P10636 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ SCD O00767 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ THRB P10828 1/20 0.35
▸ SYK P43405 2/20 0.35
▸ FYN P06241 2/20 0.34
▸ PI4KB Q9UBF8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257696 0.93 ITGB2 (0.40) ITGB2ICAM1ITGALKDM4EALDH1A1
SCHEMBL15020822 0.92 FPR2 (0.41) ITGB2ICAM1ITGALKDM4EALDH1A1
SCHEMBL15020929 0.91 ALDH1A1 (0.45) ITGB2ICAM1ITGALKDM4EALDH1A1
SCHEMBL257516 0.91 ALDH1A1 (0.45) ITGB2ICAM1ITGALKDM4EALDH1A1
SCHEMBL15020578 0.91 LMNA (0.40) ITGB2ICAM1ITGALKDM4EALDH1A1
SCHEMBL15020592 0.90 ALDH1A1 (0.43) ITGB2ICAM1ITGALKDM4EALDH1A1
SCHEMBL15020537 0.89 KDM4E (0.37) ITGB2ICAM1ITGALKDM4EALDH1A1
SCHEMBL10072360 0.88 FPR2 (0.39) KDM4EALDH1A1FPR2SCN9AMAPT
SCHEMBL15020638 0.88 FPR2 (0.39) KDM4EALDH1A1FPR2SCN9AMAPT
SCHEMBL15042195 0.88 MAPT (0.44) KDM4EALDH1A1FPR2SCN9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US claimed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 — — EP claimed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US claimed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 — — US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 — — EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 ITGB2 4807/4885ICAM1 3405/4885ITGAL 4811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback